Osteosarcoma trials

AI-generated summary

The trial tests whether regorafenib given as maintenance therapy after first-line treatment helps keep bone sarcoma from coming back. Participants are patients 12 years and older with confirmed primary bone sarcoma who have completed standard treatment and have no evidence of disease; they are randomized to regorafenib for up to 12 months or to placebo surveillance. The main goal is to see if regorafenib improves relapse-free survival and disease control, with results analyzed by high-risk versus low-risk relapse groups. Key exclusions include prior VEGFR inhibitors, certain cardiovascular problems, active infections, HIV, hepatitis B/C, pregnancy, and other conditions that could affect safety or adherence. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests regorafenib plus best supportive care as maintenance therapy for high-grade bone sarcomas after standard treatment. - It is for patients aged 12 and older with confirmed high-grade bone tumors (e.g., osteosarcoma, Ewing, chondrosarcoma, UPS, leiomyosarcoma, angiosarcoma) who have evaluable residual disease that cannot be removed and did not progress after initial therapy. - Participants will receive regorafenib with BSC for up to 12 months to see if this approach can better delay progression, with progression-free rate as a key measure. - Key exclusions include prior VEGFR inhibitors, soft tissue sarcomas, certain cardiovascular problems, active infection, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Lu-TARGO trial tests LNTH-2403, a 177Lu-labeled radiopharmaceutical, for people with relapsed or refractory osteosarcoma. It is a non-randomized, open-label study that will measure how the drug distributes in the body (dosimetry), test increasing dose levels, and then expand a cohort to gather more data. Eligible participants include those with relapsed/refractory osteosarcoma who have progressed after at least one chemotherapy course, with age groups starting at 18 years (Phase 1) and then 12 years or older in later cohorts and Phase 2, and who meet imaging and performance criteria. Key exclusions include allergy to LNTH-2403 or its components, active infection or significant other illnesses, ongoing anti-cancer therapy, pregnancy or breastfeeding, HIV, active liver disease, recent major surgery, or inability to comply with study procedures.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The SPEARHEAD-3 Pediatric Study is testing a treatment called afamitresgene autoleucel in children and teens with certain advanced cancers. It includes patients whose tumors express MAGE-A4 and who are HLA-A*02 positive, across cancers such as synovial sarcoma, MPNST, neuroblastoma, and osteosarcoma (ages 2-17 for synovial sarcoma; 2-21 for the other cancers). The study aims to assess safety and whether the treatment helps, after prior chemotherapy and with measurable disease before treatment. Key exclusions include HLA-A*02:05 positivity or similar A*02 variants, autoimmune disease, CNS metastases, active infections (HIV, HBV, HCV), pregnancy, significant cardiovascular disease, or another cancer not in remission.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a combo of AMXT 1501 and DFMO (eflornithine) in children and young adults up to age 21 with relapsed or refractory neuroblastoma, certain brain tumors (including DIPG), and some sarcomas. - The main goals are to find a safe, recommended dose of AMXT 1501 with DFMO, assess safety and tolerability, and learn whether the treatment shows activity by looking at responses and how long the disease stays under control. - The trial includes different age groups (adolescents and young adults 12 and older, and younger children under 12) with age-specific dose considerations. - Key exclusions include body surface area under 0.25 m2, current use of other investigational or anticancer drugs, active infection, or risk factors that would make safety monitoring unreliable.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study will look at the molecular, cellular, and genetic features of several pediatric solid tumors (including neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma, soft tissue sarcomas, adrenocortical tumors, and liver cancers) using gene expression analysis, SNP/genomic testing, CGH, sequencing, and electron microscopy, and it will also create tumor cell lines and animal tumor models. It will study how T cells recognize tumors by comparing T cell receptors from blood and from tumor tissue, and it will examine methylation patterns and anti-tumor T cell responses before and after PD-1 inhibition. Eligible participants are children and young adults up to age 25 with suspected or known diagnoses of these cancers, from whom tissue may be collected at biopsy, surgery, bone marrow aspiration, or relapse, with informed consent at St. Jude or collaborating sites. Exclusion: patients who are positive for Hepatitis B, Hepatitis C, or HIV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an observational, prospective study by the Italian Sarcoma Group to collect data on patients with localized high-grade osteosarcoma treated under the AIEOP/ISG OS 2021 plan. It aims to learn about patients’ demographic, clinical, surgical, pathological and molecular characteristics, the treatments they receive, and their outcomes. The study is currently recruiting. Eligibility includes people diagnosed with high-grade osteosarcoma of the arms or legs, age 40 or younger, localized disease (skip metastases allowed) and adequate organ function who give informed consent. Exclusions include the presence of metastases, periosteal or parosteal or secondary osteosarcoma, or any medical condition that would prevent receiving the recommended treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PET imaging using a radioactive form of methionine to evaluate tumors in children and young adults with cancer. It aims to find out how often MET PET can visualize tumors at diagnosis and whether MET uptake relates to tumor grade. The study also looks at how MET distributes in normal organs and how MET PET findings compare with MRI and FDG-PET CT over time. The trial is sponsored by St. Jude Children’s Research Hospital and is currently active but not recruiting. Eligible participants are patients under St. Jude care with known or suspected cancer; key exclusions include having more than six MET PET scans in the past year or an inability to give informed consent (and lactation in women of childbearing age).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests whether adding selinexor to gemcitabine helps people with selected advanced soft-tissue sarcomas (UPS, LMS, ASPS) and osteosarcoma. - It is for adults 18–80 whose disease has progressed after prior therapy, with measurable disease and good functioning (ECOG 0–1). - The trial starts with Phase I to find a safe dose, then moves to Phase II with four tumor-type groups; most groups are randomized to selinexor plus gemcitabine or gemcitabine alone, except the ASPS cohort. - Key eligibility exclusions include three or more prior chemotherapy lines, prior selinexor or gemcitabine, pregnancy, active infection, and brain metastases unless treated and stable.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a longitudinal cohort study to see if cancer treatment accelerates early aging in adolescents and young adults with cancer, by measuring aging markers before therapy and one year later. It includes patients aged 18-39 with a confirmed cancer diagnosis who are about to start systemic therapy with curative intent. The main goal is to see how the senescence marker P16 changes over one year, and it also looks at SASP, vascular markers, and cardiovascular risk factors related to treatment and patient/tumor characteristics. Measurements are taken at two visits and include blood tests and a physical exam (weight, height, waist-hip ratio, blood pressure); key exclusions are inability to understand consent, treatment with immune checkpoint inhibitors or anti-angiogenic therapy, and prior systemic therapy or radiotherapy for another cancer (with limited exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the safety and manufacturing feasibility of giving a patient’s own B7-H3-targeted CAR T cells (B7-H3CART) by IV infusion for relapsed or refractory solid tumors. It is for children and young adults aged 2 to 30 with tumors that have not responded to standard therapies, including neuroblastoma, sarcomas, Wilms tumor, and other solid tumors. The study uses a 3+3 dose-escalation design to find a safe dose and learn about how to manufacture the product and how well patients tolerate it. B7-H3 expression is not required (tumor tissue may be analyzed), and key exclusions include active infections, certain heart conditions, untreated brain metastases, pregnancy, and other active cancers or systemic immunosuppression.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests adding hydroxychloroquine to a chemotherapy combo of gemcitabine and docetaxel for people with recurrent or treatment-refractory osteosarcoma. It aims to find the maximum tolerated dose and to see if the regimen improves disease control at 4 months compared with historic results. Researchers will also look at tumor response, survival outcomes, safety, pharmacokinetics, and related biomarkers and imaging changes. Eligible participants have osteosarcoma that has recurred or not responded to standard therapy and measurable disease; key exclusions include prior gemcitabine or docetaxel, pregnancy or potential pregnancy, HIV, active infection, major heart or eye conditions, and other significant health issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests the drug ivosidenib (AG-120) in children and adolescents with advanced solid tumors, CNS tumors, lymphomas, or histiocytic disorders that have IDH1 mutations and have not responded to prior treatment. The study aims to see how often tumors shrink or disappear (objective response rate) and to learn about progression-free survival and safety in this group. Participants are aged 12 months to 21 years and must have measurable disease along with other health criteria. Ivosidenib is given by mouth once daily in 28-day cycles, for up to 2 years, to study its pharmacology and biomarkers of response. Key exclusions include pregnancy or breastfeeding, use of strong CYP3A4 inhibitors or inducers, prior exposure to IDH1 inhibitors, and receiving another investigational or anti-cancer drug at enrollment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding mifamurtide to post-operative chemotherapy improves outcomes for newly diagnosed high-risk osteosarcoma patients. It compares post-operative chemotherapy alone to post-operative chemotherapy plus mifamurtide in a multicenter, randomized, open-label design. Participants are people aged 2 to 50 with high-grade osteosarcoma who already had pre-operative chemotherapy and surgery and are considered high risk (metastases at diagnosis or poor histological response). Exclusions include low-grade osteosarcoma, active HIV or hepatitis infections, pregnancy, heart function issues, and other medical conditions that would preclude chemotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 2 pilot study testing OMO-103, a Myc inhibitor, given by intravenous infusion to see if it is safe and has anti-tumor activity in people with advanced high-grade osteosarcoma. It is open-label, unicentric, and single-arm, enrolling about 10 evaluable patients to assess anti-tumor activity and to study safety, tolerability, pharmacokinetics and pharmacodynamics. Eligible participants are people aged 12 years and older with histologically confirmed, advanced high-grade osteosarcoma not suitable for curative local treatment, whose disease has progressed after standard chemotherapy; at least 30% will be under 18, with the first three aged 12–15 under extra safety monitoring. Treatment uses 6.5 mg/kg of OMO-103 weekly by IV infusion until progression or intolerable toxicity. Key exclusions include active uncontrolled infection or HIV/HBV/HCV infection, recent systemic cancer therapy or radiation, another active malignancy, pregnancy or breastfeeding, or other conditions that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests selpercatinib, an RET pathway inhibitor, in children and adolescents with advanced solid tumors, lymphomas, or histiocytic disorders that have activating RET gene alterations. The study aims to learn how often tumors shrink or disappear (objective response rate) and how long patients stay progression-free, as well as how tolerable the drug is. Participants are ages 12 months to 21 years with measurable disease and must have recovered from prior therapy; they must not have previously received selpercatinib or other RET inhibitors. Selpercatinib is given by mouth twice daily in 28-day cycles for up to 26 cycles (about 2 years), with regular imaging and safety monitoring. Key exclusions include pregnancy, certain drug interactions (e.g., strong CYP3A4 inhibitors/inducers), recent major surgery, active infection, and uncontrolled medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This pediatric MATCH trial tests tipifarnib in children and young people aged 12 months to 21 years whose advanced solid tumors, lymphoma, or histiocytic disorders have an HRAS gene alteration. - The main goal is to see how many patients have a tumor shrinkage or disappearance (objective response) with tipifarnib. - The study also looks at progression-free survival and how well the drug is tolerated in kids and teens. - It will explore biomarkers that might predict who responds and how tumor DNA in blood changes over time. - Key exclusions include pregnancy or breastfeeding, and not being eligible if you’re on other investigational drugs or certain interacting medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests EGFR-targeted CAR T cell therapy in children and young adults with relapsed or refractory non-CNS solid tumors that express EGFR. It has two arms: Arm A uses EGFR CAR T cells alone, and Arm B adds a CD19-targeting component. It is a phase I, open-label, non-randomized trial to assess safety and feasibility, determine the maximum tolerated dose, describe the toxicity, and see how long the CAR T cells persist and act against tumors. Eligible participants include those with EGFR-expressing non-CNS solid tumors that are recurrent or refractory; early enrollees are ages 15–30, with later enrollees ages 1–30. Key exclusions include active infection, other active cancers, active CNS disease, pregnancy, and GVHD or significant immunosuppression; if severe toxicity occurs, cetuximab or trastuzumab may be used to help eliminate the CAR T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Aerosolized Aldesleukin in Treating Patients With Lung Metastases is being studied. Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma +5 • Eligibility: Inclusion Criteria: * Patients with diagnosis of advanced cancer with lung metastases; patients with no prior therapy are eligible if there is no known superior alternative medical therapy;…. Goal: This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This phase II trial tests the combination of oleclumab and durvalumab in adults (and older teens in one cohort) with sarcoma that has recurred, is refractory, or has metastasized, including angiosarcoma, dedifferentiated liposarcoma, and osteosarcoma. It aims to learn how well the treatment works by measuring tumor shrinkage at 4 months and by estimating event-free survival for osteosarcoma patients, with additional safety and survival data collected. The study will also collect biomarker and immune-system data to understand how the therapy affects tumors and immune cells. Key exclusions include prior anti-PD-1/PD-L1 or anti-CD73 therapy, active autoimmune disease, untreated CNS metastases, recent anticancer therapy, and other conditions that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) is being studied. Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma +4 • Eligibility: Procurement Inclusion Criteria: 1. Evaluable neuroblastoma with persistent or relapsed disease 1. Recurrent disease following completion of aggressive multi-drug frontline therapy. 2. Progressive disease during aggressive multi-drug frontline…. Goal: This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized, multicenter trial tests whether adding zoledronic acid to standard chemotherapy improves outcomes for people with high‑grade osteosarcoma, compared with chemotherapy alone, and it plans to enroll about 440 patients. It uses different chemotherapy regimens based on age, and some treatment arms include zoledronic acid before and after surgery. The study aims to learn whether the combination improves progression-free survival, and it also looks at overall survival, histologic response, toxicity, and quality of life. All participants have surgery after initial chemotherapy, and subsequent treatment is guided by how much tumor remains. Eligibility requires histologically confirmed high‑grade osteosarcoma and adequate organ function; key exclusions include low‑grade, small cell, maxillary, or extra‑osseous osteosarcoma, metastases not removable, prior chemotherapy or radiotherapy, dental problems, and pregnancy or related contraceptive issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests regorafenib, a broad-spectrum tyrosine kinase inhibitor, in young patients ages 9 to 21 with refractory primary bone tumors like Ewing sarcoma or osteosarcoma. It aims to see whether adding regorafenib to standard treatment can improve outcomes and to use molecular testing to guide therapy and understand prognosis. Participants must have progressed or relapsed after initial therapy and be able to swallow tablets, with informed consent and a life expectancy of at least 12 weeks. Exclusions include prior exposure to regorafenib, pregnancy or breastfeeding, and health conditions that could increase risk or interfere with results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study, currently not recruiting, tests whether CDH6 protein levels in osteosarcoma and Ewing’s sarcoma tissue can serve as a prognostic biomarker and help monitor treatment response. It includes patients over 12 years old with newly diagnosed high‑grade osteosarcoma or Ewing’s sarcoma who have not yet received first‑line chemotherapy. Researchers will measure CDH6 expression in tumor samples collected at diagnosis and around surgery to see if changes reflect chemotherapy sensitivity and prognosis. Exclusion criteria include inability to receive standardized chemotherapy and surgery at the center, not agreeing to standard follow‑up, or any condition that could harm participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests GD2-CART01, a CAR T-cell therapy made from the patient’s own T cells that targets the GD2 protein, in children and young adults with high‑risk or relapsed/refractory neuroblastoma and a small group of other GD2‑positive tumors. - It has two parts: Phase I to find a safe dose and Phase II to expand and assess efficacy. - Eligible participants will have T cells collected, engineered into GD2-CART01, receive a lymphodepleting regimen, and then a single infusion of the CAR T cells that includes a safety switch to stop activity if needed. - The study follows patients for up to 5 years after treatment; key exclusions include pregnancy, severe infections, HIV, hepatitis B or C, and certain organ dysfunction or recent conflicting therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. is being studied. Conditions: Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma +6 • Eligibility: 1. males and females aged 18-65 years; 2. Diagnosis and management at CLB for one of the following cancers: Hodgkin's lymphoma, aggressive non-Hodgkin's lymphoma, acute myeloid leukemia and…. Goal: INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests cabozantinib s-malate as a treatment for osteosarcoma or Ewing sarcoma that has relapsed or grown after standard therapy. - The study aims to see if cabozantinib can shrink tumors or stop their growth, with a focus on six-month responses measured by RECIST criteria. - It also looks at longer-term outcomes such as progression-free and overall survival, plus safety. - The trial is sponsored by the National Cancer Institute and is currently active but not recruiting. - Key exclusions include prior cabozantinib, recent cancer therapies, untreated brain metastases or major heart problems, pregnancy or breastfeeding, and HIV infection on antiretroviral therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma is being studied. Conditions: Osteosarcoma, Ewing Sarcoma • Eligibility: Inclusion Criteria: * Osteosarcoma and Ewing sarcoma first diagnosis * No previous chemotherapy treatment * ≥ 12 years old * Able to understand the questionnaire * No malignant…. Goal: Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years. For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity, insulin-resistance) are well known (breast cancer, prostate cancer, colon cancer). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Istituto Ortopedico Rizzoli.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vaccine Therapy in Treating Patients With Metastatic Cancer is being studied. Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer +8 • Eligibility: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma…. Goal: RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors is being studied. Conditions: Melanoma (Skin), Neuroblastoma, Sarcoma +1 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed neuroblastoma or melanoma at original diagnosis * Refractory to chemotherapy or recurrence after prior multiagent chemotherapy * Measurable or evaluable (detectable by bone…. Goal: RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of hu14.18-interleukin-2 fusion protein in treating children who have refractory or recurrent neuroblastoma or other tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +8 • Eligibility: DISEASE CHARACTERISTICS: Case or control patient clinically eligible for a Pediatric Oncology Group (POG) frontline therapeutic protocol, whether or not the protocol was submitted to or approved by…. Goal: RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not enroll in them, and develop strategies to increase enrollment on these clinical trials. Phase/Status/Sponsor: Unknown phase; COMPLETED; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ABT-751 in Treating Young Patients With Refractory Solid Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor\*, including, but not limited to, the following: * Rhabdomyosarcoma * Other soft tissue sarcomas * Ewing's sarcoma family of tumors *…. Goal: RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including,…. Goal: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas is being studied. Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma +26 • Eligibility: Inclusion Criteria: * Histologically confirmed refractory malignant solid tumor or lymphoma * Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification * No known…. Goal: This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors is being studied. Conditions: Glioblastoma, Rhabdomyosarcomas, Neuroblastoma +1 • Eligibility: Inclusion Criteria: * Patient's age is less than or equal to 21 years at the time of study entry. * Patient has a histologically or pathologically confirmed diagnosis…. Goal: The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. Phase/Status/Sponsor: Unknown phase; COMPLETED; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer is being studied. Conditions: Cancer • Eligibility: INCLUSION CRITERIA: * ≥ 2 years and ≤ 21 years of age at the time of study entry * Scheduled to receive chemotherapy for: * Newly diagnosed: *…. Goal: RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.